Boehringer Ingelheim's Vargatef set for EU approval
This article was originally published in Scrip
Executive Summary
The EU's CHMP has granted a positive opinion to Boehringer Ingelheim's oral triple angiokinase inhibitor Vargatef (nintedanib), paving the way for its first approval, for use in lung cancer.